{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer%27s+Disease&page=3&q=amyloid",
    "query": {
      "q": "amyloid",
      "condition": "Alzheimer's Disease",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 527,
    "total_pages": 53,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer%27s+Disease&page=4&q=amyloid&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer%27s+Disease&page=2&q=amyloid&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T11:47:30.868Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01723553",
      "title": "Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atypical Alzheimers Disease",
        "Logopenic Variant of Primary Progressive Aphasia (LPA)",
        "Posterior Cortical Atrophy (PCA)"
      ],
      "interventions": [
        {
          "name": "C-11 PiB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2012-11",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-12-21",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01723553"
    },
    {
      "nct_id": "NCT00991419",
      "title": "To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "[18F]AZD4694",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 25,
      "start_date": "2010-02",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2013-01-30",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00991419"
    },
    {
      "nct_id": "NCT04629495",
      "title": "Rapamycin - Effects on Alzheimer's and Cognitive Health",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "55 Years to 89 Years"
      },
      "enrollment_count": 40,
      "start_date": "2021-08-11",
      "completion_date": "2027-03-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04629495"
    },
    {
      "nct_id": "NCT00303277",
      "title": "Do HMG CoA Reductase Inhibitors Affect Abeta Levels?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Aging"
      ],
      "interventions": [
        {
          "name": "simvastatin",
          "type": "DRUG"
        },
        {
          "name": "pravastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seattle Institute for Biomedical and Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 35,
      "start_date": "2002-08",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2010-04-13",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00303277"
    },
    {
      "nct_id": "NCT02614131",
      "title": "A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Alzheimer's Disease",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "LY2599666",
          "type": "DRUG"
        },
        {
          "name": "Solanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo SC",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2015-12",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 3,
      "location_summary": "Glendale, California • Marlton, New Jersey • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02614131"
    },
    {
      "nct_id": "NCT00448799",
      "title": "Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimers Disease"
      ],
      "interventions": [
        {
          "name": "[123-I] AV-83 Injection and Imaging Procedures",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Molecular NeuroImaging",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2007-03",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2008-05-13",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448799"
    },
    {
      "nct_id": "NCT07142278",
      "title": "DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Alzheimer Disease (AD)",
        "Preclinical Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "DUVAX 200 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DUVAX 400 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Adjuvant only)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nuravax, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "40 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-09-25",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 1,
      "location_summary": "Miami Lakes, Florida",
      "locations": [
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07142278"
    },
    {
      "nct_id": "NCT04274998",
      "title": "Neuroinflammation Imaging in AD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "[18F]NOS",
          "type": "DRUG"
        },
        {
          "name": "[11C]PBR28",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-03-03",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04274998"
    },
    {
      "nct_id": "NCT00900770",
      "title": "Implications of Amyloid Pathology",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "60 Years to 90 Years"
      },
      "enrollment_count": 100,
      "start_date": "2008-11",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2009-12-29",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900770"
    },
    {
      "nct_id": "NCT01097096",
      "title": "Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CAD106",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "Up to 85 Years"
      },
      "enrollment_count": 177,
      "start_date": "2010-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-10-11T11:47:30.868Z",
      "location_count": 5,
      "location_summary": "Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01097096"
    }
  ]
}